InnoCare Receives IND Approval from NMPA to Initiate P-I Study of ICP-189 + Furmonertinib in NSCLC Patients
Shots:
- In the dose escalation study, the dose (120 mg) demonstrated no DLT along with favorable PK and safety profile. Preliminary efficacy was observed in ICP-189 monotx. while 1 patient with cervical cancer in the 20 mg dose cohort achieved confirmed PR
- In Jul 2023, InnoCare and ArriVent entered into a clinical development collaboration to evaluate the anti-tumor activity and safety of ICP-189 + furmonertinib in patients with advanced NSCLC
- ICP-189, a SHP2 allosteric inhibitor, in combination with furmonertinib becomes a highly brain-penetrant, while ArriVent is advancing Furmonertinib in patients with advanced or metastatic EGFR or HER2 mutations NSCLC incl. exon 20 insertion mutations. It is approved in China as a 1L treatment for NSCLC with EGFR exon 19DEL or exon 21 substitution mutations
Ref: Businesswire | Image: Innocare
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
